StockUS listing USABCLNASDAQHealthcareStructurally Challenged

Abcellera Biologics Inc(ABCL) Stock Analysis | Healthcare

USD --+0.00%
Reward35Moderate
Risk64Medium-High
75%Data
Thin -219% profit margin · Revenue growing 19% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 3.16Bn
Reward Ratingⓘ35 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ64 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ABCL to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Abcellera Biologics Inc?

engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

AI Brief Pro

The brief on Abcellera Biologics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Abcellera Biologics Inc?

engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.16B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (35)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.59
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
0
3122,778 shares
$1.4M
3-6months
0
393,587 shares
$975k
6-9months
0
4278,057 shares
$952k
9-12months
0
150,000 shares
$178k